Biopharma grants maintained their upward trajectory throughout 2023, culminating in a nearly 67% increase in value compared to 2022, mirroring the trend observed in October. Conversely, nonprofit deal value witnessed a continued year-over-year decline, falling by more than 90% in value.

Despite what appears to be a recovering public financing market for the biopharma industry, with about $20 billion raised so far through follow-on offerings in the first two months of 2024, emerging companies remain in that precarious position between dwindling cash and their next milestone inflection points.

In 2023, the BioWorld Infectious Disease Index (BIDI) concluded with a 43.48% decline, showing improvement from the 83.57% drop observed in 2022. While an uptick was seen from October's year-to-date performance, down 47.98%, BIDI still lagged both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average for the year, which saw gains of 3.74% and 13.7%, respectively.

In the first month of 2024, BioWorld reported on 252 phase I-III clinical trial updates, marking a 10% decrease from the 281 updates in December 2023, as well as a decline from 354 updates in November and 416 in October. The number of trial updates is also a 10% drop compared to January 2023, which recorded 281 updates.